Cyrielle Caussy1, Adrien Aubin2, Rohit Loomba3,4,5. 1. Hôpital Lyon Sud, Département Endocrinologie, Diabète et Nutrition, Hospices Civils de Lyon, 69495, Pierre-Bénite, France. cyrielle.caussy@chu-lyon.fr. 2. Hôpital Lyon Sud, Département Endocrinologie, Diabète et Nutrition, Hospices Civils de Lyon, 69495, Pierre-Bénite, France. 3. Department of Medicine, NAFLD Research Center, University of California at San Diego, La Jolla, CA, USA. roloomba@ucsd.edu. 4. Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. roloomba@ucsd.edu. 5. Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, CA, USA. roloomba@ucsd.edu.
Abstract
PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are strongly associated. Both also associate with an increased risk of cardiovascular disease (CVD). RECENT FINDINGS: Several studies have provided evidence that NAFLD could be an independent CVD risk factor. Given the strong association between NAFLD and T2DM, assessing the independent CV effect of these two conditions remains challenging. However, patients with T2DM and NAFLD exhibit higher risk of CVD compared with T2DM without NAFLD suggesting a potential synergistic increase of CV risk in patients with both T2DM and NAFLD supported by several shared pathophysiological pathways. Several anti-diabetic therapies have shown beneficial effect on both NAFLD and CVD. Patients with T2DM and NAFLD should be considered at high risk of CVD and could benefit from more intensive CV prevention. Additional long-term follow-up is needed to demonstrate that the treatment of NAFLD effectively reduces the risk of CVD.
PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are strongly associated. Both also associate with an increased risk of cardiovascular disease (CVD). RECENT FINDINGS: Several studies have provided evidence that NAFLD could be an independent CVD risk factor. Given the strong association between NAFLD and T2DM, assessing the independent CV effect of these two conditions remains challenging. However, patients with T2DM and NAFLD exhibit higher risk of CVD compared with T2DM without NAFLD suggesting a potential synergistic increase of CV risk in patients with both T2DM and NAFLD supported by several shared pathophysiological pathways. Several anti-diabetic therapies have shown beneficial effect on both NAFLD and CVD. Patients with T2DM and NAFLD should be considered at high risk of CVD and could benefit from more intensive CV prevention. Additional long-term follow-up is needed to demonstrate that the treatment of NAFLD effectively reduces the risk of CVD.
Authors: Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson Journal: Cell Metab Date: 2017-05-02 Impact factor: 27.287
Authors: Hertzel C Gerstein; Michael E Miller; Faramarz Ismail-Beigi; Joe Largay; Charlotte McDonald; Heather A Lochnan; Gillian L Booth Journal: Lancet Date: 2014-07-31 Impact factor: 79.321
Authors: Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell Journal: Nature Date: 2012-02-01 Impact factor: 49.962
Authors: Cyrielle Caussy; Anupriya Tripathi; Greg Humphrey; Shirin Bassirian; Seema Singh; Claire Faulkner; Ricki Bettencourt; Emily Rizo; Lisa Richards; Zhenjiang Z Xu; Michael R Downes; Ronald M Evans; David A Brenner; Claude B Sirlin; Rob Knight; Rohit Loomba Journal: Nat Commun Date: 2019-03-29 Impact factor: 14.919
Authors: Desiree M Sigala; Bettina Hieronimus; Valentina Medici; Vivien Lee; Marinelle V Nunez; Andrew A Bremer; Chad L Cox; Candice A Price; Yanet Benyam; Yasser Abdelhafez; John P McGahan; Nancy L Keim; Michael I Goran; Giovanni Pacini; Andrea Tura; Claude B Sirlin; Abhijit J Chaudhari; Peter J Havel; Kimber L Stanhope Journal: Nutrients Date: 2022-04-15 Impact factor: 6.706
Authors: Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov Journal: Int J Mol Sci Date: 2021-04-24 Impact factor: 5.923